Brief: Valneva, CSL Seqirus Enter Exclusive Agreement For Vaccine Distribution In Germany
26/06/2025 06:04
June 26 (Reuters) - Valneva SE VLS.PA: ANNOUNCES EXCLUSIVE AGREEMENT WITH CSL SEQIRUS FOR VACCINE DISTRIBUTION IN GERMANY CSL SEQIRUS TO COMMERCIALIZE VALNEVA VACCINES FROM JULY 2025 AND JANUARY 2026 NEW AGREEMENT REPLACES 2021 DEAL WITH BAVARIAN NORDIC AGREEMENT INCLUDES MINIMUM ANNUAL PURCHASING QUANTITIES AND TERMINATION CLAUSES EXPECTS PRODUCT SALES TO GROW TO €170-180 MILLION IN 2025 NEW AGREEMENT TO LAST THREE YEARS Source text: ID:nGNEb1VZPg Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency